Bang, Y. H., Kim, J. E., Lee, J. S., Kim, S. Y., Kim, K., Kim, T. W., & Hong, Y. S. (2021). Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Nature Portfolio.
Cita Chicago Style (17a ed.)Bang, Yeong Hak, Jeong Eun Kim, Ji Sung Lee, Sun Young Kim, Kyu-Pyo Kim, Tae Won Kim, y Yong Sang Hong. Bevacizumab Plus Capecitabine as Later-line Treatment for Patients with Metastatic Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. Nature Portfolio, 2021.
Cita MLA (8a ed.)Bang, Yeong Hak, et al. Bevacizumab Plus Capecitabine as Later-line Treatment for Patients with Metastatic Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. Nature Portfolio, 2021.